pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

ASTRAZENECA

USupdated 3mo ago
Website ↗
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(0)

no pipeline products on record

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase3A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)recruitingn=625
  • —Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravisrecruitingn=50
  • phase4A Study Evaluating the Safety and Effectiveness of Lokelma in Indian Patients With Hyperkalaemiarecruitingn=120
  • phase2A Study to Investigate the Efficacy and Safety of Dato-DXd-based Combinations in Participants With TROP2 NMR+ NSCLCnot yet recruitingn=250
  • —A Study for Observing Severe Asthma in Patients Treated With Tezepelumabcompletedn=513
  • —UmbREALung - A Retrospective and Prospective, Observational, Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliancerecruitingn=300
  • —Long-term Safety of Eplontersen Treated aTTR Patients and in Liver Transplant and Severely Hepatic Impaired Subpopulationsrecruitingn=320
  • phase2Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemiarecruitingn=83
🐶 Hiring Signal
No open roles indexed yet — view ASTRAZENECA jobs →

News

  • STAT+: Pharmalittle: We’re reading about Sanofi eyeing Insmed, AI speeding drug development, and more
    Sanofi weighs an Insmed takeover, the FDA slams J&J over misleading bladder cancer drug claims, and more pharma news:
    stat · 10h ago
  • Merck’s TROP2 ADC extends survival in pivotal gastroesophageal cancer trial
    Merck & Co.’s sacituzumab tirumotecan has improved overall survival in a phase 3 cancer trial, delivering a second pivotal global victory for the TROP2-directed antibody-drug conjugate.
    fiercebiotech · 16h ago
  • With FDA nod, Regeneron brings an RNAi drug to autoimmune disease
    The product of a collaboration with Alnylam, Livsayis is now Regeneron’s first marketed RNAi drug and will compete against established medicines from AstraZeneca and Argenx.
    biopharma_dive · 1d ago
  • Sanofi secures first FDA approval to treat neurological symptoms in rare metabolic disease
    Sanofi’s Infilbray is designed to cross the blood-brain barrier, allowing the drug to prevent the toxic buildup of disease-causing lipids in the brain for patients with type 3 Gaucher disease.
    biospace · 1d ago
  • Pfizer leaps into ‘in vivo’ CAR-T with latest China deal
    The potentially $2.6 billion collaboration puts Pfizer into a competitive race to treat autoimmune conditions by reprogramming cells inside the body.
    biopharma_dive · 2d ago
  • FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK
    The FDA had several issues with ivonescimab, according to the letter. Elsewhere, Sellas shares rocketed on results for a leukemia vaccine and Biogen and Lilly struck up new R&D pacts.
    biopharma_dive · 2d ago
  • In China’s shadow, Pfizer CEO calls for AI savings to bolster Big Pharma
    Speaking at the Jefferies conference in London, Pfizer CEO Albert Bourla warned of China’s rise and spoke to how companies like his can compete by leveraging AI-discovered savings.
    biospace · 2d ago
  • 5 acquisitions that forced Big Pharmas to co-parent
    Acquiring a biotech with an existing Big Pharma partner can impose financial and strategic constraints around data sharing and milestone and royalty payments—but it is “rarely a deal-breaker,” acco…
    biospace · 2d ago
  • Roche breast cancer pill cleared by FDA
    Wilserdly’s U.S. approval is seen by analysts as a “key first step” in an important launch for Roche, which has claimed the drug could become its top-selling product.
    biopharma_dive · 3d ago
  • Kyntra axes mid-stage ADC, adding to years of stumbles
    Beleaguered Kyntra Bio can’t catch a break. Formerly known as FibroGen, the company has endured a series of woes over the last few years, and now the biotech is cutting a clinical antibody-drug con…
    fiercebiotech · 3d ago
view all news mentions →
identifiers
country
US
source
openfda_drugsfda
mentioned in
10news items
entity-linker matched

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?